Cefazolin

Drug Categories
ACE Inhibitors Alpha Adrenergic Blockers Analgesics (Misc.) Anemia Medications Angiotensin II Receptor Blockers Antiarrhythmics Antibiotics Amikacin Amoxicillin Ampicillin (IV) Azithromycin Aztreonam Cefazolin Cefixime Cefotaxime Cefoxitin Ceftazidime Ceftriaxone Cefuroxime Sodium Cephalexin Ciprofloxacin Clarithromycin Clindamycin Cloxacillin Dapsone Daptomycin Doxycycline Ertapenem Erythromycin Gentamicin Imipenem/Cilastatin Levofloxacin Linezolid Meropenem Metronidazole Moxifloxacin Penicillin G Penicillin V Piperacillin/Tazobactam Streptomycin Sulfamethoxazole/Trimethoprim Tetracycline Tigecycline Tobramycin Vancomycin Antiemetics Antifungals Antihistamines Antiplatelets Antivirals Beta Blockers Calcium Channel Blockers Cardiovascular Medications (Misc.) Diabetes Medications Diuretics Dyslipidemia Medications (Misc. ) Immunosuppressants Metabolic Bone Disease Medications Miscellaneous Medications NSAIDs Opioids Proton Pump Inhibitors Psychotropics Sedatives Statins Vitamins

Drug Category	Drug	IHD Dosing	Administration Timing Around HD Session
Antibiotics	Cefazolin	1-2g IV QHD	Administer Post-HD

Molecular Weight (Da)	Excreted Unchanged (%)	Normal Half-Life (Hours)	ESRD Half-Life (Hours)	Plasma Protein Binding (%)	Volume of Distribution (L/kg)	Dialytic Plasma Clearance (ml/min)	% Dialyzed
454	75-95	2	40-70	80	0.13-0.22	15-38	27-50 (high flux)

References:

Ahern J, Possidente C, Hood V, Alston W. Cefazolin dosing protocol for patients receiving long-term hemodialysis. AJHP (American journal of health-system pharmacy) 2003; 178-81.
Andriole V. Pharmacokinetics of Cephalosporin in Patients with Normal or Reduced Renal Function. Journal of Infectious Diseases 1987; 137(Supplement), S88-97.
Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
Brogard J, Pinget M, Brandt C, Lavillaureix J. Pharamacokinetics of Cefazolin in Patients with Renal Failure; Special Reference to Hemodialysis. The Journal of Clinical Pharmacology 1977; 17(4), 225-230.
Czerwinski A, Pederson J, Barry J. Cefazolin Plasma Concentrations and Urinary Excretion in Patients with Renal Impairment. The Journal of Clinical Pharmacology 1974; 14, 560-6.
DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01327
Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
Kuypers D, Vanwalleghem J, Maes B, Messiaen T, Vanrenterghem Y, Peetermans W. Cefazolin serum concentrations with fixed intravenous dosing in patients on chronic hemodialysis treatment. Nephrology, dialysis, transplantation (official publication of the European Dialysis and Transplant Association - European Renal Association) 1999; 14(8), 2050-1.
Matzke G. Status of Hemodialysis of Drugs in 2002. Journal of Pharmacy Practice 2002; 15(5), 405-418.
Maynor L, Carl D, Matzke G et al. An in vivo-in vitro study of cefepime and cefazolin dialytic clearance during high-flux hemodialysis. Pharmacotherapy 2008; 28(8), 977-83.
Sowinski K, Mueller B, Grabe D et al. Cefazolin Dialytic Clearance by High-Efficiency and High-Flux Hemodialyzers. American Journal of Kidney Diseases 2001; 37(4), 766-776.